Amarin appoints Jan van Heek non-executive director

16-Feb-2010 - Ireland

Amarin Corporation plc announced the appointment of Mr. Jan van Heek to its board of directors as a non-executive director. As part of his board role, Mr. van Heek has been appointed Chairman of the Company’s Audit Committee.

Mr. van Heek (age 60) brings significant international business experience to Amarin from a career spanning more than 30 years in the healthcare industry. He is currently a Principal and Partner at BioPoint Group, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development.

Prior to establishing BioPoint, Mr. van Heek spent more than 18 years at Genzyme Corporation, most recently as Senior Advisor to the CEO and senior management team. Mr.van Heek joined Genzyme in 1991, where as Executive Vice President, he was largely responsible for establishing and building its worldwide therapeutics, surgical and genetic testing businesses.

Prior to Genzyme, Mr. van Heek held various management positions at Baxter Healthcare Corporation in Europe and the US. He received an M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.

Mr. van Heek is currently a board member of PanGenetics BV in the Netherlands and was a board member of and Chairman of the Audit Committee of ViaCell Corporation, a US public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. Between 2007 and 2009, he was Chairman of the Board of BioVex Inc. in Woburn, MA and where he also chaired its Audit and Compensation Committees. Mr. van Heek also served on the board of Zelos Therapeutics, Inc. between 2004 and 2008.

https://www.bionity.com/en/news/113402/amarin-appoints-jan-van-heek-non-executive-director.html